Amad Ali, Jardri Renaud, Rousseau Chloé, Larochelle Yann, Ioannidis John P A, Naudet Florian
Psychiatry Department and CURE Platform, Fontan Hospital, CHU Lille, Lille, France,
Psychiatry and Beliefs Team, SCALab, CNRS UMR-9193, University of Lille, Lille, France,
Psychother Psychosom. 2019;88(6):363-370. doi: 10.1159/000502805. Epub 2019 Oct 7.
Repetitive transcranial magnetic stimulation (rTMS) has been widely tested and promoted for use in multiple neuropsychiatric conditions, but as for many other medical devices, some gaps may exist in the literature and the evidence base for the clinical efficacy of rTMS remains under debate.
We aimed to test for an excess number of statistically significant results in the literature on the therapeutic efficacy of rTMS across a wide range of meta-analyses and to characterize the power of studies included in these meta-analyses.
Based on power calculations, we computed the expected number of "positive" datasets for a medium effect size (standardized mean difference, SMD = 0.30) and compared it with the number of observed "positive" datasets. Sensitivity analyses considered small (SMD = 0.20), modest (SMD = 0.50), and large (SMD = 0.80) effect sizes.
A total of 14 meta-analyses with 228 datasets (110 for neurological disorders and 118 for psychiatric disorders) were assessed. For SMD = 0.3, the number of observed "positive" studies (n = 94) was larger than expected (n = 35). We found evidence for an excess of significant findings overall (p < 0.0001) and in 8/14 meta-analyses. Evidence for an excess of significant findings was also observed for SMD = 0.5 for neurological disorders. Of the 228 datasets, 0 (0%), 0 (0%), 3 (1%), and 53 (23%) had a power >0.80, respectively, for SMDs of 0.30, 0.20, 0.50, and 0.80.
Most studies in the rTMS literature are underpowered. This results in fragmentation and waste of research efforts. The somewhat high frequency of "positive" results seems spurious and may reflect bias. Caution is warranted in accepting rTMS as an established treatment for neuropsychiatric conditions.
重复经颅磁刺激(rTMS)已在多种神经精神疾病中得到广泛测试和推广,但与许多其他医疗设备一样,文献中可能存在一些空白,rTMS临床疗效的证据基础仍存在争议。
我们旨在通过广泛的荟萃分析,检验rTMS治疗效果文献中统计显著结果的数量是否过多,并描述这些荟萃分析中所纳入研究的效能。
基于效能计算,我们计算了中等效应量(标准化均数差,SMD = 0.30)下“阳性”数据集的预期数量,并将其与观察到的“阳性”数据集数量进行比较。敏感性分析考虑了小(SMD = 0.20)、中等(SMD = 0.50)和大(SMD = 0.80)效应量。
共评估了14项荟萃分析,包含228个数据集(110个用于神经系统疾病,118个用于精神疾病)。对于SMD = 0.3,观察到的“阳性”研究数量(n = 94)多于预期(n = 35)。我们发现总体上(p < 0.0001)以及在14项荟萃分析中的8项中存在显著结果过多的证据。对于神经系统疾病,在SMD = 0.5时也观察到显著结果过多的证据。在228个数据集中,对于SMD分别为0.30、0.20、0.50和0.80时,效能>0.80的数据集分别有0(0%)、0(0%)、3(1%)和53(23%)。
rTMS文献中的大多数研究效能不足。这导致了研究工作的碎片化和浪费。“阳性”结果出现频率偏高似乎存在虚假性,可能反映了偏差。在将rTMS接受为神经精神疾病的既定治疗方法时应谨慎。